Why Lantheus Holdings Stock Got Thrashed on Tuesday
Radiopharmaceutical specialist Lantheus Holdings (LNTH -7.30%) had some news to report Tuesday morning, but the market didn't greet it warmly. Following its announcement of a fresh acquisition, inv...
Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer's ...
Enhances Lantheus' growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's Disease
Lantheus Holdings: Powerhouse Potential In 2025
Lantheus Holdings is a strong buy due to its dominant market position and promising growth prospects in radiopharmaceuticals and Alzheimer's diagnostics. PYLARIFY, Lantheus' top revenue generator, ...
2 Stock Market Predictions for 2025: 2 Stocks Worth Buying No Matter What Happens
In this video, Motley Fool contributors Jason Hall and Tyler Crowe make two predictions about the market in 2025, and also share two stock picks they think will do well no matter what happens with ...
Lantheus Announces Share Repurchase Program
BEDFORD, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians ...
Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY'...
BEDFORD, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinici...
Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cance...
Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Com...
Radiopharm Receives Strategic Investment for up to A$18 million
SYDNEY, June 20, 2024 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or the Company), a developer of diagnostic and therapeutic radiopharmaceutical products, has entered ...
Best Momentum Stocks to Buy for May 31st
MNSO, LNTH and LXFR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 31, 2023.
Is Lantheus Holdings (LNTH) a Solid Growth Stock? 3 Reasons to Think "Yes"
Lantheus Holdings (LNTH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Wall Street Analysts Believe Lantheus Holdings (LNTH) Could Rally 31.21%: Here's is How to Trade
The mean of analysts' price targets for Lantheus Holdings (LNTH) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement a...
Lantheus (LNTH) Q1 Earnings Surpass Estimates, Gross Margin Up
Lantheus' (LNTH) robust revenues from the majority of its segments drive its first-quarter performance.
Lantheus Holdings, Inc. (LNTH) Q1 2024 Earnings Call Transcript
Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Mark Kinarney - Vice President of Investor Relations Brian Markison - Chief Execu...
Lantheus Holdings (LNTH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Lantheus Holdings (LNTH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metr...
Lantheus Holdings (LNTH) Q1 Earnings and Revenues Beat Estimates
Lantheus Holdings (LNTH) came out with quarterly earnings of $1.69 per share, beating the Zacks Consensus Estimate of $1.55 per share. This compares to earnings of $1.47 per share a year ago.
Related Companies